Overview

Hydroxychloroquine in Prevention of Preeclampsia

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:
0

Participant gender:
Female

Summary

Pre-eclampsia complicates up to 8% of pregnancies and is a major contributor to maternal mortality and morbidity The only effective treatment is delivery, which leads to significant neonatal morbidity and mortality if carried out preterm, especially when the disease occurs early in pregnancy. Vascular endothelial dysfunction and immunological impairment are associated with preeclampsia. To date, there is no effective or optimal therapeutic approach for these conditions. Hydroxychloroquine has endothelial protective action via ant diabetic, lipid lowering, antioxidant effects or direct endothelial protection. Hydroxychloroquine is an antimalarial and immunomodulatory agent. In pregnancy, hydroxychloroquine is prescribed for inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve placental function in pregnancies associated with heightened inflammation.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Treatments:

Aspirin
Folic Acid
Hydroxychloroquine

Criteria

Inclusion Criteria:

- Pregnant women in 1st 6 weeks gestation.

- Women willing to participate.

Exclusion Criteria:

- Known contraindication to treatment by Hydroxychloroquine (

- Patients already using Hydroxychloroquine

- Impossible to follow-up.